Literature DB >> 3183704

The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy.

J L Richardson1, G Marks, A Levine.   

Abstract

To provide a systematic analysis of how adverse symptoms of disease and side effects of cancer therapy relate to patient noncompliance with treatment, we interviewed 107 patients with hematologic malignancies at the initiation of therapy and 6 months later to collect information on the type, frequency, and difficulty of unpleasant physical effects experienced. Level of compliance was monitored (biochemically and with self-report) on a monthly basis for oral self administration of allopurinol and prednisone. Appointment-keeping to receive infused chemotherapy was also monitored. Nausea was the most frequent side effect experienced. Nausea, fever, and pain were the most difficult physical effects to tolerate when they occurred. Complex treatment regimens and severe diseases related to reports of more physical effects. Younger patients had a more difficult time dealing with these effects than did older patients. Neither the occurrence, frequency, or difficulty dealing with any of the effects related to noncompliance with either of the two self-administered medications. Difficulty with particular effects did relate to noncompliance with clinic appointments to receive infused chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183704     DOI: 10.1200/JCO.1988.6.11.1746

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  47 in total

Review 1.  Biobehavioral outcomes following psychological interventions for cancer patients.

Authors:  Barbara L Andersen
Journal:  J Consult Clin Psychol       Date:  2002-06

2.  Electronic monitor for patient compliance with drug therapy.

Authors:  P W Nicholson
Journal:  Med Biol Eng Comput       Date:  1991-11       Impact factor: 2.602

3.  Quality-of-life assessment in cancer clinical trials: an intervention by itself?

Authors:  J Bernhard; H Gusset; C Hürny
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

4.  Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.

Authors:  Cesare Gridelli; Amin M Haiderali; Mark W Russo; Linda M Blackburn; Konstantinos Lykopoulos
Journal:  Support Care Cancer       Date:  2009-10-31       Impact factor: 3.603

5.  The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Veerisa Vimolchalao; Siwat Sakdejayont; Ploytuangporn Wongchanapai; Shama Sukprakun; Pattama Angspatt; Wilai Thawinwisan; Piyachut Chenaksara; Virote Sriuranpong; Chanida Vinayanuwatikun; Napa Parinyanitikun; Nattaya Poovorawan; Suebpong Tanasanvimon
Journal:  Int J Clin Oncol       Date:  2019-11-27       Impact factor: 3.402

Review 6.  Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  G L Plosker; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 7.  Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?

Authors:  Jill M Kolesar; Jens Eickhoff; Lee C Vermeulen
Journal:  Am J Health Syst Pharm       Date:  2014-03-15       Impact factor: 2.637

8.  Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients.

Authors:  Wadih Rhondali; Sriram Yennurajalingam; Gary Chisholm; Jeanette Ferrer; Sun Hyun Kim; Jung Hun Kang; Marilene Filbet; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2013-04-16       Impact factor: 3.603

9.  Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial.

Authors:  Barbara L Andersen; William B Farrar; Deanna M Golden-Kreutz; Ronald Glaser; Charles F Emery; Timothy R Crespin; Charles L Shapiro; William E Carson
Journal:  J Clin Oncol       Date:  2004-09-01       Impact factor: 44.544

Review 10.  The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

Authors:  Michael S Broder; Claudio Faria; Annette Powers; Jehangeer Sunderji; Dasha Cherepanov
Journal:  Am Health Drug Benefits       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.